Next-Gen Single-Cell Sequencing Workflow Slashes Prep Time to Under Ten Hours

BioSkryb Genomics and Tecan’s new high-efficiency single-cell multiomics workflow promises a revolutionary reduction in library prep time, signaling a major leap for precision medicine and pharmaceutical innovation.

In a significant leap for precision medicine and life sciences, BioSkryb Genomics and Tecan have jointly unveiled a streamlined single-cell multiomics workflow capable of generating sequencing-ready libraries in less than ten hours. This collaboration marks a pivotal advancement in an industry where traditional workflows have historically stretched over multiple days, burdened by manual steps and potential variability. The newly introduced system integrates BioSkryb’s ResolveDNA technology with Tecan’s Fluent Automation Workstation, forming a robust, fully automated platform. This end-to-end solution not only expedites the process but also enhances reproducibility, a critical factor in clinical and pharmaceutical research environments where consistency underpins credibility. The automation minimizes human intervention, reducing the risk of errors and freeing up skilled labor for higher-value analytical tasks—an industrial automation milestone reshaping how labs operate globally.

For pharmaceutics and life science industries, this development opens avenues for faster therapeutic discoveries and more personalized treatment strategies. Researchers can now compress the time from sample acquisition to actionable data, offering pharmaceutical companies an opportunity to speed up drug development pipelines without sacrificing data integrity. The new workflow’s compatibility with multiple omics analyses simultaneously—genomic, transcriptomic, and beyond—further cements its value in the era of systems biology.

The implications stretch beyond laboratories. Organizations investing in faster and more reliable single-cell analysis tools stand to gain competitive advantages in clinical trials, biomarker discovery, and regulatory submissions. As the global race intensifies to harness the full potential of single-cell insights, early adopters of such automation will likely lead the next wave of biopharmaceutical breakthroughs. By bridging efficiency and precision, BioSkryb and Tecan have set a new benchmark for laboratory automation, signaling a future where agility and accuracy are no longer trade-offs but twin pillars of success.